TARGET AUDIENCE This activity is intended for neurologists, nurses, nurse practitioners, physician assistants, rehabilitation professionals, case managers, mental health professionals, social workers and others involved in the management of patients with MS.
STATEMENT OF NEED
The number of FDA-approved disease modifying therapies (DMTs) for patients with MS has grown considerably over the last 2 decades. These agents vary by mechanism of action, mode of administration, dosing frequency, side effect profiles and monitoring recommendations. The increasing range of treatment options allows for individualized treatment selection for this patient population and it is critical that clinicians managing patients with MS are familiar with current evidence to support optimal treatment decisions over the disease course. In addition, a multi-dimensional, comprehensive care approach is advocated to promote positive outcomes for individuals with MS. All members of the MS health care team need awareness of how to incorporate the principles of comprehensive care in clinical practice. There are no fees for participating in and receiving credit for this activity. 2. Review the activity objectives and CME/CNE information. 3. Complete the CME/CNE activity. 4 . Go to www.cmeAIMS.org/AIMS-primer and complete the posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
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5. Complete the CME/CNE evaluation/attestation form at www.cmeAIMS.org/AIMS-primer, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs. 6. Your CME/CNE certificate will be available for download.
ACCREDITED PROVIDER
This activity is provided by the Consortium of Multiple Sclerosis Centers and Nurse Practitioner Alternatives in collaboration with The France Foundation.
ACCREDITATION STATEMENT
The Consortium of Multiple Sclerosis Centers is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION
Physicians: The Consortium of Multiple Sclerosis Centers designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses: Nurse Practitioner Alternatives is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is awarded 2.0 contact hour(s) of continuing nursing education for RNs and APRNs.
Laurie Scudder, DNP, NP, has served as Nurse Planner for this activity. She has declared that she has no relevant financial relationships to disclose.
DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, Consortium of Multiple Sclerosis Centers (CMSC), Nurse Practitioner Alternatives (NPA), and The France Foundation (TFF) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. CMSC, NPA, and TFF resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC, NPA, and TFF to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC, NPA, and TFF committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
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FACULTY DISCLOSURES
The following faculty report that they have relevant financial relationships to disclose: Perhaps the most commonly proposed hypothesis for the development of MS is one of peripheral autoimmune activation, where T cells are primed against myelin antigens and demyelination occurs as a consequence of immune mediated mechanisms. This hypothesis is supported by the effect of immune modulating therapies in modifying the disease course. 4 There is also clear evidence of clonal expansion of both T and B cells in MS lesions suggesting both humoral and cell mediated immunity play cardinal roles in disease pathology. An alternate hypothesis suggests that a primary event occurring in the CNS may trigger a secondary immune activation response and the resulting injury of grey and white matter. 5 However, what this primary inciting event would be has yet to be discovered. Several factors have been studied and are known to produce an increased risk of MS and may help us understand some clues regarding the etiology of the disease (Table 1) . 
MS Pathophysiology and Disease Course
Neurodegeneration
Significant advances have been made in the concepts that help to explain the progressive worsening of neurological function, most evidently seen in progressive forms of MS. 19 Understanding these mechanisms is of importance if we are to develop therapies that might provide neuroprotective effects in progressive stages of the disease (Figure 2 ). Figure 3 ).
This progressive form of the disease is characterized by mechanisms of neurodegeneration without focal inflammation and poor response to immune modulating medications.
To facilitate diagnosis, classification, and clinical care, disease categories have been developed that classify the disorder in relapsing remitting (RRMS), secondary progressive (SPMS), and primary progressive MS (PPMS) disease courses. 22 Most patients (~85%) begin with a relapsing remitting (RRMS) form of the disease, and may then develop gradual accumulation of disability independent of relapses (SPMS). A minority of patients begin the disease with a progressive course from the onset with no clinical relapses (PPMS). The updated disease course descriptors include qualifiers of clinical relapse rate, imaging findings, and disease progression to describe overall MS activity. 23 The core phenotypes of relapsing-remitting and progressive disease have been retained. Clinically isolated syndrome (CIS), an initial neurological disturbance lasting more than 24 hours with signs and symptoms consistent with an inflammatory demyelinating disorder (that could be MS), is now included in the 2013 phenotypes. CIS and RRMS are further classified as 'active' or 'not active,' with 'active' indicating clinical and/or radiological activity (relapses, gadolinium-enhancing MRI lesions, new or enlarging T2 lesions). Progressive disease (primary or secondary) is now sub-classified as 'active with progression;' 'active but without progression;' 'not active but with progression;' and 'not active and without progression.' 'Progression' in this context refers to gradual accumulation of disability. 
AIMS NEUROMYELITIS OPTICA SPECTRUM DISORDERS
Neuromyelitis optica (NMO) is an autoimmune, inflammatory disorder of the CNS that primarily targets the optic nerves and spinal cord causing optic neuritis and transverse myelitis. The pathogenic antibody aquaporin 4 IgG (AQP4, also known as NMO-IgG), was discovered in 2004 and is highly specific for the disease. 24 These antibodies can be tested in the serum and CSF.
Prior to the discovery of this antibody, the disease was initially named Devic's disease and was believed to be a monophasic condition, which caused concomitant bilateral optic neuritis and transverse myelitis. Eventually, relapsing cases were reported.
In 2006, the AQP4 autoantibody test was included in the diagnostic criteria for NMO. 25 These diagnostic criteria included two major criteria, 
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history of optic neuritis and transverse myelitis, along with at least two of three supportive criteria: AQP4 seropositivity; myelitis extending over ≥ 3 vertebral bodies in length termed longitudinally extensive transverse myelitis (LETM); and/or brain MRI not meeting diagnostic criteria for MS. 25 These criteria were more relaxed and allowed the diagnosis to be made even if patients were found to have lesions within the brain outside of optic nerve and spinal cord or if they had unilateral optic neuritis. Later, NMO Spectrum Disorders (NMOSD) were identified to include individuals with AQP4 seropositivity who presented with an initial attack and/or patients not yet meeting full NMO criteria, but who were identified to be at risk for further attacks. The NMOSD also included patients with other presentations localizing to the cerebrum, diencephalic and brainstem regions. In addition, patients with co-existent autoimmune diseases such as systemic lupus or Sjogren's syndrome who were found to also be seropositive forAQP4 IgG were included under the NMOSD category.
Making the proper diagnosis of NMO/NMOSD versus MS as early as possible is important as some MS disease modifying therapies appear to worsen disease activity in NMO. [26] [27] [28] Furthermore, disability in NMO is dependent upon relapses, which are often more severe with less recovery than those occurring in MS.
In 2015, the International Panel for NMO Diagnosis (INPD) was formed and revised NMO diagnostic criteria were developed to incorporate new knowledge and to help aid in earlier diagnosis of this disorder (Table 2) . 29 In the new criteria the terms NMO and NMOSD have been unified to NMOSD with AQP4 IgG Positivity and NMOSD without AQP4 IgG Positivity or unknown AQP4 IgG status.
Currently there are no FDA-approved treatments for NMOSD, but off-label oral immunosuppressants (mycophenolate, azathioprine, prednisone) and off label-intravenous rituximab (a chimeric monoclonal antibody resulting in B cell depletion) have all shown benefit in case series and observational studies. 30 Phase 3 clinical trials are currently underway to study treatment options for NMOSD. These placebo-controlled studies are separately evaluating eculizumab, a terminal complement inhibitor, in the PREVENT trial; MEDI-551, a humanized monoclonal antibody targeting CD19 resulting in B cell depletion; and SA237, an anti-IL-6 receptor antibody.
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A multidimensional, comprehensive care approach is advocated to optimize outcomes for patients with MS. 34 Comprehensive care is patient-centered, multidisciplinary care provided by a team that adopts a whole-person orientation. The patient is viewed as an integral team member, and is empowered to actively participate in care planning and self-care actions. Comprehensive care encompasses relapse management, disease modifying therapies (DMTs), symptom management, psychosocial support, and rehabilitation.
Currently approved DMTs for MS are summarized in Table 3 .
General Framework for the Management of MS
Glatiramer acetate (Copaxone ® )
Glatiramer acetate (Glatopa™) 
MRI:
The formal recommendation of the CMSC MRI Task Force is to obtain an MRI of the brain with and without gadolinium at baseline, prior to starting or switching MS DMTs, and at least once every 1-2 years while on an MS DMT to assess for subclinical disease activity. 36 In clinical practice, MRI every 6 or 12 months may be needed for selected patients. It is also recommended to obtain an MRI of the brain 6 months after starting an MS DMT to establish a new baseline. Routine spinal cord monitoring MRIs are not recommended unless the presentation is mostly recurrent TM. There may now be a trend to monitor the spinal cord for asymptomatic lesions, particularly in patients with radiologically isolated syndrome (RIS). 37 It is useful to obtain a spine MRI at baseline if relapse history is consistent with spinal cord localization.
MS Relapses:
Generally an MS relapse is defined as a new neurologic symptom with onset in the absence of fever or infection lasting longer than 24 hours.
Safety: Depends on specific DMT and standard monitoring guidelines should be followed.
Side Effects & Tolerability: If the DMT is causing a patient side effects and/or lowering their quality of life, the neurologist/care team should consider alternative DMT options that may be better tolerated (for example, if a patient experiences significant pain and injection site reactions on interferon, a switch to an oral DMT may be considered).
Adherence: If a patient is unable to take their DMT regularly as directed, it will not be as effective and thus, strategies for improving adherence on their current therapy may be explored (examples include use of a pill box, setting alarms, or a calendar). In addition, one may consider switching to an alternate DMT in which the patient may have improved adherence. For example, for a patient who cannot remember to take a pill twice daily (dimethyl fumarate), they may have improved adherence on a once daily therapy (fingolimod).
Disease-free status or no evidence of disease activity (NEDA) has become a therapeutic goal for the treatment of patients with MS ( Figure 7) . NEDA has been defined as the absence of new or enlarging T2 lesions or T1 gadolinium-enhancing lesions on MRI, and no sustained EDSS score progression or clinical relapse. 38 Some authors have also suggested inclusion of brain atrophy measures and patient-related outcome measures in NEDA. 39 Treatment switches may be considered for a number of reasons including lack of efficacy (breakthrough disease), safety concerns, tolerability and difficulty with adherence. For example: if a patient is on an injectable therapy and has evidence of disease activity based on MRI, neurologic examination or MS relapses, neurologists should consider advancing the patient's therapy to an oral therapy (teriflunomide, DMF or fingolimod) or an infusion (natalizumab, alemtuzumab). There is no universal treatment algorithm as each patient's disease course is unique. Patients on natalizumab may need to switch to alternative MS therapies due to increased risk of PML with time on treatment or many other reasons. Natalizumab treated patients often have a more aggressive MS phenotype as they may have had a suboptimal response to alternative MS DMTs and thus, are at higher risk of recurrence of MS disease activity with treatment interruption. The RESTORE trial demonstrated an increased risk of disease activity with treatment interruption up to 24 weeks in patients who had been stable for at least one year 40 A washout (time off DMT) is often considered in between therapies to ensure that there are not overlapping effects with immunomodulatory therapy that could potentially result in increased risk of infection. This must be carefully balanced as washing out may lead to increased risk of MS relapse or new MRI disease activity. Clinicians may consider limiting time off treatment during a washout as the RESTORE trial demonstrated that clinical activity/relapses occurred as early as 4-8 weeks and radiographic disease activity as early as 12 weeks. 40 The therapy selected to switch onto after natalizumab depends on reasons for discontinuation and each individual patient's disease course. Studies have evaluated the switch from natalizumab to fingolimod and demonstrated that limiting the length of washout is beneficial in preventing new MS disease activity. 41, 42 An observational comparative effectiveness study showed that patients switching to fingolimod vs. interferon beta or glatiramer acetate after natalizumab suspension were less likely to suffer a relapse. 44 A new preparation of GA with less frequent dosing was approved in 2014 based on the results of the GALA trial. 44 The GALA trial studied GA at 40 mg subcutaneous injection three times weekly vs. placebo. The new formulation demonstrated 34% reduction in risk of relapse, 45% reduction in gadolinium enhancing lesions and 35% reduction in new or enlarging T2 lesions as compared to placebo. 45 An open-label, randomized, multicenter study (GLACIER) was conducted to evaluate the safety and tolerability of GA 40 mg three times weekly compared with GA 20 mg daily in patients with RRMS. 46 GLACIER demonstrated that GA 40 mg three times weekly was well tolerated with a favorable side effect profile as compared to 20 mg once daily (50% reduction in annualized rate of injection-related adverse events). 46 A generic version of GA 20 mg (daily subcutaneous injection) received FDA approval in April of 2015. 47 
Interferon
Interferon beta therapies have remained a standard of care treatment for RRMS for over 20 years, but these agents vary in the frequency of administration and type of injection (subcutaneous vs. intramuscular). Pegylated interferon beta-1a (PEG IFNβ-1a) was developed by attaching a polyethylene glycol side-chain to the interferon molecule via pegylation. This modification confers prolonged half-life allowing for less frequent administration. 48 FDA-approved in 2014, PEG IFNβ-1a is a subcutaneous injection (125 µg) administered every two weeks for RRMS. The ADVANCE trial demonstrated significant reduction in annualized relapse rate (36% reduction), disability progression (38% reduction) and MRI outcomes (67% reduction in new or enlarging T2 lesions and 86% reduction in gadolinium enhancing lesions) for PEG IFNβ-1a as compared to placebo. 48 The reported side effect profile for PEG IFNβ-1a is similar to that of other interferons.
ORAL THERAPY UPDATES AND NEW SAFETY CONCERNS Dimethyl Fumarate
Dimethyl fumarate (DMF) is a twice daily oral therapy for RRMS. 49 Anti-inflammatory and cytoprotective effects of DMF are proposed to be mediated via the Nrf2 pathway, and a shift from Th1 to Th2 cytokine response. 50 There is a rare risk of progressive multifocal leukoencephalopathy (PML) in patients on DMF. 51, 52 Rare cases of PML have been reported in patients on DMF associated with lymphopenia. 49, 51, 53, 54 In three patients, the absolute lymphocyte count was less than 500 cells/μL for 1-4 years and in one patient the absolute lymphocyte count was 600 cells/μL for greater than 6 months. 51, 54 According to the label, a baseline CBC with differential should be checked and once DMF is initiated, it should be checked every 6-12 months thereafter. 49 If the absolute lymphocyte count drops below 500 cells/μL for greater than 6 months, treatment interruption should be considered. 49 
Fingolimod
Fingolimod, the first oral-therapy approved for RRMS (FDA approved in 2010), is a sphingosine-1-phosphate receptor modulator that prevents lymphocyte egress from lymph nodes into the periphery. 55, 56 In phase 3 clinical trials, treatment with fingolimod was associated with 50% reduction in ARR compared with placebo or IFNβ-1a. [56] [57] [58] 55 Infectious risks remain a concern on fingolimod due to rare reports of fingolimod-associated zoster virus infections, PML, and cryptococcal infections (cutaneous, pulmonary and meningitis). 59 Rare cases of PML have been reported with fingolimod. 55 The mechanism of PML associated with fingolimod remains unclear.
Teriflunomide
Teriflunomide is a once daily oral therapy FDA approved in 2012 for RRMS (available in 14 mg and 7 mg doses). 60 The exact mechanism of action for teriflunomide is unknown, but likely involves reduction in the number of lymphocytes entering the CNS by inhibiting dihydroorotate dehydrogenase, a mitochondrial enzyme involved in pyrimidine synthesis in rapidly proliferating cells. 61 Teriflunomide is pregnancy category X and both women and men planning to conceive should undergo a rapid elimination procedure utilizing activated charcoal or cholestyramine (teriflunomide is slowly eliminated from the plasma). 62 Teriflunomide carries a black box warning for hepatotoxicity. No cases of PML have been reported with teriflunomide. At ECTRIMS 2015, Kappos et al reported on 2.5 year follow-up of the TOWER extension study in patients with RRMS. 63 These authors reported no new safety signals with teriflunomide treatment in the extension study, and an adverse event profile consistent with that seen in core studies, supporting a positive benefit vs. risk ratio for patients with RRMS. 63 
INFUSION THERAPIES Natalizumab
Natalizumab is a humanized, monoclonal antibody which inhibits α4β1-integrin mediated adhesion of leukocytes to VCAM-1 on vascular endothelial cells at the blood brain barrier, thus preventing leukocyte migration into the brain and is administered IV once every 28 days. 64 The Tysabri Observational Program (TOP) is an open-label, international, phase IV, prospective observational study designed to evaluate the long-term safety and impact on disease activity and progression of natalizumab monotherapy in patients with RRMS. 65 Interim results from TOP have demonstrated that annualized relapse rates remain low, EDSS remains stable, and no change in known safety concerns have occurred for up to 5 years following natalizumab treatment initiation. [66] [67] [68] A nine-year post-marketing surveillance study demonstrated no increased risk of malignancy with natalizumab treatment as compared to the general population. 69 The rare risk of PML should continue to be closely monitored in patients on natalizumab using a JCV serum antibody test prior to treatment initiation and periodically while on treatment (Table 4 ). 
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Updates on the Treatment of RRMS 18 AIMS For patients who are JCV positive, the patient's JCV serum antibody index value may be taken into account to further clarify risk of PML (Table 5) . Natalizumab use in patients with history of prior immunosuppressant therapy is not recommended in patients who are JCV serum Ab positive due to increased risk of PML. PML risk increases beyond 24 doses. All patients on natalizumab must be enrolled in TOUCH, an observational risk monitoring program.
64
Alemtuzumab
Alemtuzumab is a humanized anti-CD52 monoclonal antibody FDA approved in 2014 for RRMS in individuals who have failed prior disease modifying therapies. 71 It is an intravenous infusion administered in two courses; once daily (12 mg/day) for 5 days in year 1 and once daily for 3 days 12 months following the first treatment course. 71 The therapy is not recommended for re-dosing unless the patient experiences new evidence of disease activity.
Alemtuzumab was FDA approved based on clinical efficacy results from the CARE MS I (treatment naive RRMS) and CARE MS II (RRMS with 1 or more relapses on prior DMT) phase 3 clinical trials comparing alemtuzumab vs. IFNβ-1a 44 mcg three times weekly. 72, 73 Results from the CARE MS I and II extension trials have recently been reported, and demonstrate continued clinical efficacy in patients treated with alemtuzumab. During the extension studies, as-needed retreatment with alemtuzumab was available ≥ 1 year apart based on evidence of disease activity (MRI activity or relapse). In CARE MS I, 5-year extension results showed that 68% of subjects were not re-dosed after month 12 and 69-72% of patients were free of new MRI disease activity at year 3, 4 and 5. 74 In CARE MS II, 5-year extension results demonstrated that 60% of patients were not re-dosed after month 12, 75% were free of sustained disability accumulation and 68-70% were free from new MRI disease activity in years 3, 4 and 5. 75, 76 Due to serious risks associated with alemtuzumab, there is a REMS program in place for all patients treated with alemtuzumab with serum and urine test monitoring once monthly for 48 months after their last infusion (Table 6 ). According to the label, risks associated with alemtuzumab include: ITP (2%), glomerular nephropathies (0.3%), autoimmune thyroid disease (34%), infections (herpes viral infections 16%, HPV 2%, active and latent TB 0.3%, listeria monocytogenes within first month of treatment, pneumonitis (0.5%), rare cases of thyroid cancer, and infusion reactions (92% total; 3% rated as severe infusion reactions). 
AIMS EMERGING THERAPIES IN RELAPSING MULTIPLE SCLEROSIS Daclizumab
Daclizumab high-yield process (HYP) is a humanized monoclonal antibody targeting CD25, the alpha subunit of the IL-2 receptor. 77 Recently published results of DECIDE, a phase 3 clinical trial, demonstrated that daclizumab HYP 150 mg subcutaneous every 4 weeks met the study primary endpoint with a 45% reduction in ARR as compared to IFNβ-1a intramuscular (30 µg) once weekly. 77 Additionally, treatment with daclizumab was associated with a 54% reduction in new or enlarging T2 lesions on MRI. There was no difference in disability progression between the two treatment arms. Notable adverse events associated with daclizumab were cutaneous events including rash and eczema, and elevation of liver enzymes up to 5x the upper limit of normal. 77 
Ocrelizumab
Ocrelizumab (OCR) a humanized monoclonal antibody targeting CD20, is being studied in two identical double-blind, double-dummy phase 3 clinical trials (OPERA I and OPERA II) in patients with RRMS. 78, 79 Recently presented primary outcome results demonstrated that treatment with OCR 600 mg intravenous administered every 6 months was associated a 46-47% reduction in ARR compared to IFNβ-1a 44 mcg subcutaneous three times weekly. 80 Confirmed disability progression was reduced by 43% and 37% in the OCR arms in the two studies. Furthermore, a 94-95% reduction in number of T1 gadolinium enhancing lesions and a 77-83% reduction in new or enlarging T2 lesions on MRI was associated with OCR treatment as compared to interferon beta-1a. 80 Infusion related reactions were more common in the OCR arms and serious infections were similar for the OCR and interferon treatment arms.
Anti-LINGO
A different therapeutic strategy being explored for MS involves anti-LINGO-1 (BIIB033), a humanized monoclonal antibody that antagonizes LINGO-1. In animal models blockade of LINGO-1 has been shown to promote myelin repair. 81 RENEW is a phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy of anti-LINGO in individuals experiencing their first acute optic neuritis.
82
Patients treated with high dose corticosteroids were randomized to anti-LINGO 100 mg/kg IV every 4 weeks (6 doses) or placebo. Treatment with anti-LINGO was associated with improvement in optic nerve latency, as measured by full field visual evoked potential, consistent with remyelination in this patient population. 83 The results of the RENEW trial provide support for further evaluation of anti-LINGO in patients with RRMS. Current treatment of progressive MS is mainly focused on symptomatic management, rehabilitation and control of complications. Effective treatment is paramount to maintain the quality of life for progressive MS patients; however the current need is for disease modifying neuroprotective, neuro-restorative therapies. We will review selected completed and ongoing trials of significance in progressive MS.
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FINGOLIMOD
Fingolimod, a sphingosine-1-phosphate receptor modulator, is an FDA-approved once-daily oral medication for relapsing forms of multiple sclerosis. 55 Data from phase 3 trials in patients with RRMS demonstrated a significant effect of fingolimod on brain atrophy in this patient population. 86 INFORMS was a three year, phase 3, double-blind, randomized multicenter, placebo controlled trial examining the effect of fingolimod 0.5 mg daily versus placebo in patients with PPMS. 87 Eligibility criteria were clinical diagnosis of PPMS, 2-10 year disease duration, and evidence of disability progression in the previous 2 years. The primary endpoint was 3-month confirmed disability progression, based on a composite of change from baseline in EDSS, 25-foot Timed Walk Test, or 9-Hole Peg Test. The study randomized 970 subjects from 158 different sites. The primary endpoint was not met, and percent brain volume change was also not different between the fingolimod and placebo groups. 88 
OCRELIZUMAB
In recognition of the role of B cells in the pathophysiology of MS, targeting this cell population has been investigated as a disease modifying strategy. Monoclonal antibodies that target CD20 such as rituximab, ocrelizumab, and ofatumumab produce prolonged depletion of B lymphocytes through complement-dependent cytotoxicity, stimulation of apoptosis, and/or antibody-dependent cytotoxicity. 89 Hawker et al evaluated rituximab (a chimeric anti-CD20 monoclonal antibody) in a phase 3 trial of patients with PPMS. 90 Treatment with rituximab was not associated with a significant difference in time to confirmed disease progression relative to placebo in this study; however these authors reported a benefit in subgroup analysis of patients younger than 51 years and those with gadolinium enhancing lesions at baseline. 90 A newer humanized anti-CD20 monoclonal antibody, ocrelizumab, has been studied in both RRMS and PPMS. Positive results were recently reported with ocrelizumab in the OPERA I and OPERA II trials in patients with RRMS. 80 A phase 3 randomized parallel group double blind placebo controlled study of ocrelziumab versus placebo (ORATORIO) in PPMS has completed enrollment of over 700 subjects with results expected in 2017. 91 Patients were randomized to 2:1 to receive either
Treatment of Progressive MS
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Treatment of Progressive MS 22 AIMS ocrelizumab (300 mg IV, two infusions, 14 days apart) or placebo every 24 weeks for at least 120 weeks. Eligible patients were 18-55 years of age, with a diagnosis of PPMS, EDSS score 3.0 to 6.5 at screening, and disease duration < 15 years for EDSS > 5.0 and < 10 years for EDSS ≤ 5.0. The primary endpoint for the ORATORIO trial is time to onset of confirmed disability progression (≥ 12-week sustained increase in EDSS scores). At ECTRIMS, Montalban et al reported that ocrelizumab treatment was associated with a 24% reduction in clinical disability progression at 12 weeks vs placebo. 92 Demonstrated benefits in MRI endpoints and whole brain volume loss were also demonstrated for ocrelizumab treatment compared with placebo. 92 
HIGH DOSE BIOTIN
Biotin (vitamin H, vitamin B7) is a vitamin coenzyme for carboxylases involved in key steps in energy metabolism and fatty acid synthesis. 93 In addition, biotin activates an enzyme involved in myelin synthesis. In a non-controlled pilot study of patients with primary or secondary progressive MS, high dose biotin (100-600 mg/day) was associated with improvement or normalization of both clinical and paraclinical measures (visual evoked potentials, proton magnetic spectroscopy). 94 This proof of concept study led to an ongoing phase 3 clinical trial in patients with primary or secondary progressive MS. 95 Eligible patients met diagnostic criteria for secondary or primary MS with EDSS between 4.5 and 7.0 and evidence of EDSS progression within the last two years. Patients were randomized to high dose biotin (300 mg daily) or placebo for 24 months. The primary endpoint was defined as the proportion of patients who improved at 9 months, with confirmation at 12 months. Improvement was defined as either a decrease in EDSS or improvement in T25FW of ≥ 20%. Tourbah et al recently reported preliminary results from this study. 96 Approximately 13% of patients in the biotin arm had an improvement in EDSS while none in the placebo arm had improvement. 96 Although the differences were statistically significant, the low proportion of responders, and lack of imaging data (atrophy) make the results unclear. Further results of this study are expected to be published soon. Whether the effect seen was a purely symptomatic improvement versus actual disease modifying activity also is still not known.
IBUDILAST
Ibudilast is a phosphodiesterase inhibitor that was studied in a phase 2 study in patients with RRMS. 97 Barkhof et al reported that in this patient population, ibudilast (30 or 60 mg/day orally) demonstrated no significant effect on lesions or relapses; however a significant benefit was noted with the 60 mg dose in protective effects on brain atrophy. 97 The authors interpreted these data as potential neuroprotective properties associated with ibudilast. 97 Ibudilast is currently being investigated in a multi-center, placebo controlled, double blind, Phase 2 study in patients with progressive MS (SPRINT-MS). 98 Eligible patients are randomized to ibudilast (up to 100 mg/day) or placebo for 96 weeks. The primary outcome measures are adjusted mean rate of change in brain atrophy over 96 weeks as measured by brain parenchymal fraction and safety. A total of 255 patients have been recruited into the trial, and results are expected in 2017.
SIMVASTATIN
Although statins have been studied in relapsing forms of MS with un-convincing results, a large phase 2 study in SPMS demonstrated a beneficial effect of simvastatin (80 mg daily) on brain atrophy. 99 Simvastatin reduced annualized atrophy by 43% compared to placebo. The possibility of a phase 3 trial however is unclear given the medication is off patent. 100 
NATALIZUMAB
The safety and efficacy of natalizumab to slow the accumulation of disability progression in patients with secondary progressive MS was evaluated in According to recent reports, 2-10% of all patients with MS have clinical onset before the age of 18 years. 103 Female gender, BMI, exposure to second-hand smoke, ≥ 1 HLA-DRB3 alleles, and remote EBV infection are risk factors for pediatric MS susceptibility or disease activity. 103 Primary progressive MS is extremely rare in children; 97% of those with disease onset prior to age 18 have relapsing-remitting disease. Compared to adult-onset MS, childhood onset-MS is associated with increased T2 MRI burden at disease onset, and frequent cognitive deficits, yet slower EDSS-related disability progression. 104 In addition, relapse frequency is higher in children within the initial 2-5 years of MS disease onset compared with adults with MS. 104 Aubert-Broche et al evaluated age-expected brain growth in patients with MS onset prior to age 18 compared with ageand sex-matched controls. 105 These authors reported that MS onset during childhood and adolescence is associated with abnormally small brain volumes, and in particular, reduction of age-expected thalamic volume-evidence of neurodegeneration early in the disease (even in children). 105 (Table 9 ). 112 This study, which included 1571 cases and 3371 controls, showed that subjects with BMI > 27 kg/m 2 at age 20 had a two-fold increased risk of developing MS compared with normal weight subjects. 112 These authors speculate that the obesity epidemic may explain part of the increasing MS incidence as recorded in some countries, and further that measures addressing adolescent obesity may serve as a preventive strategy against MS. 112 Ben-Zacharia recently reported results of a 5 year retrospective study evaluating the association between baseline BMI and MS progression. 113 This study showed that the odds of having increased EDSS by at least 1 point in obese patients with mild disability were 8 times greater than for those with normal BMI. 113 In addition, the odds of having new brain MRI lesions were 6.2 times greater in overweight subjects and 2.6 times greater in obese subjects than in subjects with normal BMI. 113 These results highlight the importance of weight control and potential benefits with regard to disease progression in this patient population.
Pediatric MS
MS
SMOKING
In 1964, the Surgeon General reported the hazards of cigarette smoking. 114 In addition to the general health and safety concerns, evidence is mounting on how smoking can affect MS. Cigarette smoking is a known risk factor for MS, and smokers are more likely to be diagnosed with progressive MS than never-smokers. 115, 116 In addition, Healy et al reported that compared with never-smokers, current smokers had significantly worse disease at baseline (EDSS scores, multiple sclerosis severity score, and brain parenchymal fraction), and converted from RRMS to secondary progressive MS faster than non-smokers. 117 
VITAMIN D
Vitamin D insufficiency is a risk factor for MS, 6, 118 and Runia et al have reported that low serum vitamin D levels are associated with a higher risk for relapse in patients with MS. 119 A recent paper by Dr. Allen Bowling recommends considering vitamin D status as part of an overall therapeutic strategy for patients with MS. 120 MS patients are at higher risk for osteopenia/osteoporosis especially if they are not ambulatory, have gait disturbance and have been treated with courses of IV steroids. Many MS patients tend to avoid being out in the sun as they are heat sensitive, further increasing their risk for Vitamin D deficiency. 121 Vitamin D deficiencies are relatively common (an estimated 80% of those with MS have levels below 20 ng/mL independent of disease stage) and can be detected by blood testing measuring 25-hydroxyvitamin D. 122 Monitoring serum vitamin D in patients with MS at baseline, with recheck at 3 to 6 months following initiation of a supplementation protocol or change in treatment regimen is recommended. 120 While a definitive protocol for vitamin D supplementation for persons with MS has not been established, a desirable range for serum vitamin D levels of 30-55 ng/mL has been suggested; supplementation with 1,000 to 4,000 IU/day may 
COMORBIDITIES
Many individuals with MS will also be diagnosed with other medical conditions in their lifetime. There is increasing evidence that the presence of comorbidity (physical or mental) in patients with MS is associated with diagnostic delays, disability progression, health-related quality of life, and progression of lesion burden on MRI. 123 Reported prevalence of comorbidity in patients with MS in the literature is variable, due to characteristics of the study population and specific conditions studied. Marrie et al recently conducted a systematic review of the incidence and prevalence of comorbidity in MS. Their study included 249 publications, based on studies conducted primarily in Europe and North America, with fewer studies from Asia, Australia, New Zealand and South America. 123 Based on their meta-analysis, the most common comorbidities were depression (23.7%), anxiety (21.9%), hypertension (18.6%), irritable bowel syndrome (12.2%), hyperlipidemia (10.9%), and chronic lung disease (10.0%). 123 An earlier study of patients in the North American Research on Multiple Sclerosis (NARCOMS) registry indicated that 36.7% of this patient population self-reported at least one physical comorbidity. 123 Among the NARCOMS population, the most frequently reported comorbidities were hyperlipidemia (37%), hypertension (30%), arthritis (16%), irritable bowel syndrome (13%), and lung disease (13%). 124 Comorbid conditions such as diabetes, hypertension, hyperlipidemia, obesity, and smoking have been shown to affect the progression of MS. 125, 126 As part of individualized treatment for patients with MS, the presence of comorbid medical and/or psychiatric conditions is an important consideration with selection of DMT and symptomatic MS The report concluded that the data were insufficient to determine if CAM therapies worsen MS or interfere with DMTs. Inquiry by the care team about the use of CAM in patients with MS is warranted, as some strategies may actually stimulate the immune system, which would not be advantageous for this patient population. Drs. Allen and Nathaniel Bowling provide information about a range of alternative medicinal approaches and considerations for use in patients with MS (http://www.neurologycare.net/cam).
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In addition, the NIH has a website (https://nccih.nih.gov/) with extensive information about complementary and integrative health, including searchable safety information for products/practices and uses and side effects of herbs and botanicals. 
